Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Challenges for Clinical Drug Development in Pulmonary Fibrosis
Eric S. White, Matthew J. Thomas, Susanne Stowasser, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis
J. Cooley, N. Javkhlan, J. Wilson, et al.
JCI Insight (2023) Vol. 8, Iss. 3
Open Access | Times Cited: 32
Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside
Mohamed A. Ghonim, David F. Boyd, Tim Flerlage, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 17
Open Access | Times Cited: 24
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
Iris K. Lee, Estela Noguera-Ortega, Zebin Xiao, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 24, pp. 5330-5342
Open Access | Times Cited: 33
Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis
Shiao‐Ya Hong, Yating Lu, Shih‐Yu Chen, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 6
Open Access | Times Cited: 21
Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases
Letícia Kawano-Dourado, Tejaswini Kulkarni, Christopher J. Ryerson, et al.
Thorax (2024) Vol. 79, Iss. 8, pp. 788-795
Open Access | Times Cited: 8
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis
Chan Ho Lee, Se Hyun Kwak, Jisu Han, et al.
European Respiratory Journal (2024) Vol. 63, Iss. 5, pp. 2300580-2300580
Open Access | Times Cited: 5
New therapeutic approaches against pulmonary fibrosis
Dongke Yu, Xiang Yu, Tingting Gou, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106592-106592
Closed Access | Times Cited: 12
Noninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1
Philip Z. Mannes, Taylor Adams, Samaneh Farsijani, et al.
Science Advances (2024) Vol. 10, Iss. 25
Open Access | Times Cited: 4
Role of Macrophage in Pathogenesis of Pulmonary Fibrosis: A Review
M. Hasan, Xuan Zhang
Advances in Lung Cancer (2025) Vol. 14, Iss. 01, pp. 1-17
Open Access
Widening Patient Engagement for Rare Disease Drug Trials: The Perspectives of Patients With Idiopathic Pulmonary Fibrosis on Participating in Clinical Drug Trials and Drug Trial Design
Julia Frost, Jessica Mandizha, Steve Jones, et al.
Health Expectations (2025) Vol. 28, Iss. 2
Open Access
Piceatannol-mediated JAK2/STAT3 signaling pathway inhibition contributes to the alleviation of oxidative injury and collagen synthesis during pulmonary fibrosis
T. Zhu, Ying Zhang, Xinghua Zhang, et al.
International Immunopharmacology (2022) Vol. 111, pp. 109107-109107
Closed Access | Times Cited: 15
Biodistribution, Dosimetry, and Pharmacokinetics of68Ga-CBP8: A Type I Collagen–Targeted PET Probe
David Izquierdo‐Garcia, Pauline Désogère, Mariane Le Fur, et al.
Journal of Nuclear Medicine (2022) Vol. 64, Iss. 5, pp. 775-781
Open Access | Times Cited: 14
Fibroblasts are not just fibroblasts: clear differences between dermal and pulmonary fibroblasts’ response to fibrotic growth factors
S. F. Madsen, Jannie Marie Bülow Sand, Pernille Juhl, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Acute exacerbation of idiopathic pulmonary fibrosis model in the rats using bleomycin and lipopolysaccharides
Sandy Vitria Kurniawan, Melva Louisa, Jamal Zaini, et al.
Journal of Advanced Veterinary and Animal Research (2023) Vol. 10, Iss. 2, pp. 196-196
Open Access | Times Cited: 7
Micro-CT-assisted identification of the optimal time-window for antifibrotic treatment in a bleomycin mouse model of long-lasting pulmonary fibrosis
Martina Buccardi, Andrea Grandi, Erica Ferrini, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy
Julia F. Söllner, Stefan Bentink, Christian Heßlinger, et al.
Lung (2024) Vol. 202, Iss. 5, pp. 595-599
Open Access | Times Cited: 2
The mechanism of Qingwen Gupi decoction on pulmonary fibrosis based on metabolomics and intestinal flora
Chen Gao, Hong Chang, Zixuan Wang, et al.
Journal of Applied Microbiology (2022) Vol. 134, Iss. 1
Open Access | Times Cited: 10
Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
Tu H, Lyrialle W. Han, Joy C. Hsu, et al.
Therapeutic Advances in Respiratory Disease (2023) Vol. 17
Open Access | Times Cited: 6
Dinebra retroflexa Herbal Phytotherapy: A Simulation Study Based on Bleomycin-Induced Pulmonary Fibrosis Retraction Potential in Swiss Albino Rats
Atef A. El‐Hela, Mostafa M. Hegazy, Hatem S. Abbass, et al.
Medicina (2022) Vol. 58, Iss. 12, pp. 1719-1719
Open Access | Times Cited: 8
Getting the Timing Right: Controlling BCL-2 Inhibition as an Antifibrotic Therapy
J. Cooley, Elizabeth F. Redente
American Journal of Respiratory Cell and Molecular Biology (2024) Vol. 70, Iss. 4, pp. 231-232
Closed Access | Times Cited: 1
An Allysine-Conjugatable Probe for Fluorogenically Imaging Fibrosis
Yilian Zhuang, Tao Yin, Jia Li, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 22, pp. 9034-9042
Closed Access | Times Cited: 1
Further Developments towards a Minimal Potent Derivative of Human Relaxin-2
Thomas N. G. Handley, Praveen Praveen, Julien Tailhades, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12670-12670
Open Access | Times Cited: 3
PGF2α signaling drives fibrotic remodeling and fibroblast population dynamics in mice
L. Raposo Rodríguez, Soon Yew Tang, W. Roque Barboza, et al.
JCI Insight (2023) Vol. 8, Iss. 24
Open Access | Times Cited: 3
Harnessing the translational power of bleomycin model: new insights to guide drug discovery for idiopathic pulmonary fibrosis
Annalisa Murgo, Fabio Bignami, Giuseppina Federico, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations
Steven J.M. Jones, Maxine Flewett, Ron Flewett, et al.
ERJ Open Research (2023) Vol. 9, Iss. 3, pp. 00602-2022
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top